Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Changes in Beneficial Ownership · 4

Applied Therapeutics Inc.

Changes in Beneficial Ownership

Filed Feb 4, 2026Accepted Feb 4, 2026, 6:17 AM ESTFiling CIK 1697532Accession 0001193125-26-036963
Share

Structured filing — 4

ownership.xml

Open full document ↗

Filing details

Report period
2026-02-03
Issuer
Applied Therapeutics, Inc.
Issuer CIK
0001697532
Trading symbol
APLT
No longer subject to Section 16
Checked

Reporting owner 1

Name
Kanter Stacy J.
Reporting owner CIK
0001775404
Relationship
Director
Address
C/O APPLIED THERAPEUTICS, INC., 545 FIFTH AVENUE, SUITE 1400, NEW YORK, NY, 10017

Non-derivative transactions

Non-derivative transactions · 2 reported rows
SecurityTransaction dateCodeAmountA / DPrice (USD)Owned afterOwnership
Common Stock2026-02-03D · Form 4[F1][F2]22,500D[F1][F2]42,500D
Common Stock2026-02-03U · Form 4[F1][F3]42,500D[F1][F3]0D
Table key
D · Form 4
Disposition to the issuer under Rule 16b-3(e)
D
Direct
U · Form 4
Shares tendered in a change of control

Derivative transactions

Derivative transactions · 5 reported rows
SecurityConversion / exercise price (USD)Transaction dateCodeAmountA / DPrice (USD)ExercisableExpiresUnderlying securityUnderlying sharesOwned afterOwnership
Stock Option (Right to Buy)1.052026-02-03D · Form 420,460D[F4][F4][F4]Common Stock20,4600D
Stock Option (Right to Buy)1.052026-02-03D · Form 410,230D[F4][F4][F4]Common Stock10,2300D
Stock Option (Right to Buy)1.052026-02-03D · Form 416,500D[F4][F4][F4]Common Stock16,5000D
Stock Option (Right to Buy)1.052026-02-03D · Form 416,500D[F4][F4][F4]Common Stock16,5000D
Stock Option (Right to Buy)0.3952026-02-03D · Form 4200,000D[F4][F4][F4]Common Stock200,0000D
Table key
D · Form 4
Disposition to the issuer under Rule 16b-3(e)
D
Direct

Footnotes

F1
Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement") dated as of December, 11, 2025, among the Issuer, Cycle Group Holdings Limited and AT2B, INC. ("Purchaser"), Purchaser completed a tender offer for shares of Issuer and thereafter merged with and into the Issuer (the "Merger"), effective as of January 28, 2026, with the Issuer surviving the Merger. At the effective time of the Merger (the "Effective Time"), each outstanding share of Issuer common stock was cancelled and converted into the right to receive (i) $0.088 per share of common stock, net to the seller in cash, without interest (the "Closing Amount") plus (ii) one non-tradeable contingent value right, in accordance with the terms and subject to the conditions of a contingent value rights agreement (the "Merger Consideration").↩ 1↩ 2↩ 3↩ 4
F2
Pursuant to the Merger Agreement, at the Effective Time, each outstanding RSU (whether vested or unvested) was deemed to have vested and was cancelled and automatically converted into the right to receive the Merger Consideration.↩ 1↩ 2
F3
Pursuant to the Merger Agreement, each share of common stock tendered by the Reporting Person was tendered in exchange for the Merger Consideration.↩ 1↩ 2
F4
Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of common stock (each a "Stock Option") that has a per share exercise price that equals or exceeds the Closing Amount as of immediately prior to the Effective time (each such Stock Option, an "Out-of-the-Money Option"), to the extent not vested, was fully vested as of prior to the Effective Time. Any Out-of-the-Money Options that remained outstanding and unexercised as of the Effective Time were cancelled for no consideration at the Effective Time.↩ 1↩ 2↩ 3↩ 4↩ 5↩ 6↩ 7↩ 8↩ 9↩ 10↩ 11↩ 12↩ 13↩ 14↩ 15

Signature 1

Signed
/s/ Leslie D. Funtleyder, as attorney-in-fact
Date
2026-02-04

Company context

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to the development of novel drug candidates against validated molecular targets in rare diseases. The Company’s lead drug candidate, govorestat, is a novel central nervous system (CNS) penetrant Aldose Reductase Inhibitor (ARI) for the treatment of CNS rare metabolic diseases, including Classic Galactosemia, Charcot-Marie-Tooth Sorbitol Dehydrogenase Deficiency (CMT-SORD) and phosphomannomutase 2 congenital disorder of glycosylation (PMM2-CDG).

Historical securities (1)

Recent company filings

  1. SCHEDULE 13G/A - filed by Vestal Point Capital, LP regarding Applied Therapeutics, Inc.Feb 17, 2026
  2. 15-12G filingFeb 13, 2026
  3. EFFECT filingFeb 6, 2026
  4. EFFECT filingFeb 6, 2026
  5. 4 filingFeb 3, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.